Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOXIRI for advanced unresectable recurrent or metastatic pancreatic cancer (first-line)
ChiCTR2100044005Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Mar 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tegafur, oxaliplatin and irinotecan in pancreatic cancer (PC), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective Response Rate. Started Mar 2021; status: recruiting.
02
Drugs
tegafuroxaliplatinirinotecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2100044005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044005.